[Federal Register Volume 59, Number 223 (Monday, November 21, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-28642]


[[Page Unknown]]

[Federal Register: November 21, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Health Care Policy and Research

 

Notice of Review of Medical Technology

    The Agency for Health Care Policy and Research (AHCPR), through its 
Office of Health Technology Assessment (OHTA), announces that it is 
initiating a Health Technology Review of the safety and effectiveness 
of bone marrow transplantation for hematopoietic reconstitution in 
patients given high-dose chemotherapy for the treatment of multiple 
myeloma.
    Specifically, AHCPR is requesting information on:
    1. Indications and/or contraindications for the use of bone marrow 
transplantation in this patient population,
    2. Specific patient selection criteria for the use of bone marrow 
transplantation, and
    3. Information regarding the cost of this technology.
    Health Technology Reviews are brief evaluations of health 
technologies prepared by OHTA/AHCPR of the Public Health Service. 
Reviews may be conducted in lieu of a technology assessment because: 
the medical or scientific questions are limited and do not warrant the 
resources required for a full assessment; the available evidence is 
limited and the published medical or scientific literature is 
insufficient in quality or quantity for an assessment; or the time 
frame available precludes utilization of the full, formal assessment 
process.
    AHCPR is interested in receiving information based on review and 
assessment of past, current, and planned research related to this 
technology, as well as a bibliography of published, controlled clinical 
trials and other well-designed clinical studies. Also requested is 
information related to the characteristics of the patient population 
most likely to benefit from the use of bone marrow transplants in the 
treatment of multiple myeloma as well as information on the clinical 
acceptability, effectiveness, and the extent of use of this technology. 
Information relevant to this review should be submitted in writing no 
later than [insert date 90 days after the date of publication] to OHTA 
at the address below.
    To enable the interested scientific community to evaluate the 
information included in this review, AHCPR will discuss in the review 
only those data and analyses for which a source(s) can be cited. 
Respondents are therefore encouraged to include with their submission a 
written consent permitting AHCPR to cite the source of the data and 
comments provided. Otherwise, in accordance with the confidentiality 
statute governing information collected by AHCPR, 42 U.S.C. 299a-1(c), 
no information received will be published or disclosed which could 
identify an individual or entity described in the information or could 
identify an entity or individual supplying the information.
    Written material should be submitted to: Thomas V. Holohan, M.D., 
Director, Office of Health Technology Assessment, AHCPR, 6000 Executive 
Boulevard, Suite 309, Rockville, MD 20852, Phone: (301) 594-4023.

    Dated: November 9, 1994.
Clifton R. Gaus,
Administrator.
[FR Doc. 94-28642 Filed 11-18-94; 8:45 am]
BILLING CODE 4160-90-P